New drug avelumab aims to keep upper tract cancer at bay after chemo

NCT ID NCT07225374

Recruiting now Disease control Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether the immunotherapy drug avelumab can help prevent upper tract urothelial carcinoma from coming back after patients have already received cisplatin-based chemotherapy. About 48 adults with high-risk muscle-invasive or node-positive disease who show no signs of cancer after chemo will receive avelumab infusions every two weeks for up to a year. The main goal is to see how long they remain cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: avelumab
What this could lead to: If successful, this could offer a way to keep upper tract cancer from coming back after chemotherapy, potentially extending the time patients stay cancer-free.
What could go wrong: This is a small, early-phase trial with only 48 participants, so results may not apply to everyone. Avelumab can cause immune-related side effects, and the treatment may not prevent recurrence in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UPPER TRACT UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal pelvis/ureter urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UPPER TRACT UROTHELIAL CARCINOMA

Contacts and locations

Locations

Samsung Medical Center
RECRUITING

Seoul, Gangnam, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.